XBiotech Inc. develops True Human™ monoclonal antibodies derived from human donors for inflammatory, oncology, neurologic, and infectious disease applications. Company news centers on its antibody platform, Natrunix, an anti-interleukin-1alpha candidate studied in pancreatic cancer and rheumatology, and Hutrukin, a candidate therapy for reducing brain injury after ischemic stroke.
Recurring developments include clinical study results, program-prioritization decisions, FDA-related clinical authorizations, enrollment updates, and the company’s Austin campus operations, including GMP manufacturing, research laboratories, infectious disease facilities, quality control, and clinical operations.
XBiotech Inc. (NASDAQ: XBIT) announced promising new data regarding its FLUVID™ therapy for treating co-infections of influenza and COVID-19. The therapy's antibodies neutralize test viruses four times more effectively than those under FDA consideration for emergency use. Research indicates a 100% survival rate in animal models given lethal flu doses. With the resurgence of COVID-19 this flu season, FLUVID™ aims to fill a critical treatment gap for patients facing these concurrent illnesses. Developed from years of research, FLUVID™ targets multiple influenza strains alongside COVID-19.
XBiotech Inc. (NASDAQ: XBIT) has announced the development of FLUVID™, a potential breakthrough therapy aimed at treating co-infections from influenza and COVID-19. As flu season approaches, FLUVID is intended to provide immunity and facilitate treatment for these dual infections. The therapy combines XBiotech’s True Human antibodies for influenza, targeting all known strains, with newly discovered COVID-19 antibodies. This integrated approach aims to harness human immunity to combat both viruses effectively.
XBiotech Inc. (NASDAQ: XBIT) has received FDA emergency use authorization for its COVID-19 Convalescent Plasma (CCP) treatment in collaboration with BioBridge Global. This test identifies antibodies from recovered COVID-19 patients, aiding the production of convalescent plasma to treat hospitalized patients. Preliminary studies indicate a 35% better survival rate for treated patients. XBiotech is also advancing its pipeline of True Human therapeutic antibodies. The company is expanding its facilities to enhance research and production capabilities.
XBiotech Inc. (NASDAQ: XBIT) announced it has identified True Human antibodies that could serve as a potential therapy against SARS-CoV2, the virus causing COVID-19. This discovery arose from collaboration with BioBridge Global, utilizing proprietary screening technology to analyze blood samples from individuals who recovered quickly from the virus. XBiotech's antibodies effectively block the virus and promote natural clearance. The company continues to expand its pipeline, including developing multiple therapeutic candidates and enhancing its manufacturing capabilities.
XBiotech Inc. (NASDAQ: XBIT) announces progress in developing a novel anti-IL-1⍺ antibody to combat inflammation. This new product aims to replace a prior antibody sold for $750 million. The company has successfully engineered a cell-based production system for the new antibody, which targets diseases like cancer and arthritis. Significant findings suggest potential for a blockbuster therapy, as recent research indicates the antibody can reduce stroke-related brain injury. XBiotech also plans to expand its manufacturing facilities to support ongoing projects.
XBiotech Inc. (NASDAQ: XBIT) announced significant findings in the journal Circulation regarding its anti-IL-1⍺ antibody. The study, led by Dr. Giovanni Camici, indicates this antibody can reduce brain damage and neurological deficits in experimental stroke cases. Results showed a 36% reduction in brain damage in treated animals. XBiotech is set to begin human clinical studies for its stroke candidate in 2021, addressing a critical need for therapies targeting reperfusion injury, which currently has no approved treatment.
Summary not available.